Last updated 11 days ago
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
286 patients around the world
Available in Puerto Rico, Argentina, United States
Jazz Pharmaceuticals
3Research sites
286Patients around the world
This study is for people with
Bile Duct Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
SponsorJazz Pharmaceuticals
Conditions
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06282575
